When a blood clot occurs, your body may naturally dissolve it through an internal “clot-busting” process. At the same time, anticoagulant medications (blood thinners) can keep a clot from growing larger and can also prevent new clots from forming. But in a small number of patients who’ve had blood clots in their lungs—a pulmonary embolism (PE)—the clots don’t go away, resulting in a condition called chronic thromboembolic pulmonary hypertension (CTEPH).

**WHAT IS CTEPH?**

“To really grasp CTEPH, patients need to understand the concepts put forth by the term itself, so 1) chronic thromboembolism and 2) pulmonary hypertension,” says Dr. Bill Auger, a pulmonologist and CTEPH specialist at the Temple University Lewis Katz School of Medicine.

So, how does a “fresh” or new blood clot turn into a “chronic” blood clot? “In some individuals who have a PE, the clot sticks to the wall of the pulmonary arteries and forms scar-like material within the artery over time. This material can narrow or block the artery. If it’s there long enough, you can then develop pulmonary hypertension (PH). In other words, these clots are the chronic thromboemboli that lead to PH in CTEPH,” Dr. Auger explains.

Anticoagulants (blood thinners) can be lifesaving if you have atrial fibrillation (Afib) or a history of blood clots. They’re also widely used to prevent clots in patients who are hospitalized or undergoing surgery. But like all medications, they have side effects. Although rare, anticoagulants can cause fatal bleeding (such as a brain bleed) in some patients. More commonly, patients may have minor bleeding while on a blood thinner. Nuisance bleeding—including nose bleeds, bleeding gums,
Dr. Melissa Pynnonen, a Professor of Otolaryngology and Medical Director at University of Michigan who specializes in nuisance bleeding. If you take an anticoagulant, there are several steps you can take to prevent and manage nuisance bleeding. It's also important to know when to seek medical attention. (See next page.)

Outside of medical emergencies, following commonsense practices and taking your anticoagulant as directed can help you stay safe and avoid blood clots.

“Stopping blood thinners can lead to a blood clot in the legs (deep vein thrombosis, DVT) or the lungs (pulmonary embolism, PE), or to a heart attack or stroke. All of these conditions can be fatal, which is why patients should never stop their anticoagulant medication without speaking to their doctor,” says Dr. Pynnonen.

Dr. Pynnonen is board certified in otolaryngology and has clinical expertise in acute and chronic sinusitis, tumors involving the nasal cavity and sinuses, and treating epistaxis (nuisance nosebleeds). Her research is focused on understanding the determinants and consequences of medical uncertainty in health care.

For more information, please visit www.natfonline.org/events or email events@natfonline.org.
HOW TO MANAGE NUISIBLE BLEEDING AT HOME

If you do experience a nuisance bleed, don’t panic. Remember that most minor bleeds are manageable at home.

- If you cut yourself, apply firm pressure for five minutes.
- There are many over-the-counter (OTC) products that can be used to stop bleeding, including bandages, clotting sponges, or protective gels.
- Similarly, there are several OTC nasal sprays that can be used to stop nuisance nosebleeds. Look for nasal sprays that contain phenylephrine or oxymetazoline. Dr. Pynnonen recommends leaning forward, spraying 3 droplets in the nostril that’s bleeding, and pinching the soft part of the nose for 10 minutes. If the bleeding doesn’t stop, soak a cotton ball in nasal spray, place it into the bleeding nostril, and pinch again for 10 minutes.
- If you believe that your bleed warrants a trip to the ER, try contacting your healthcare provider before you go.
- Do NOT stop taking your anticoagulant unless directed by your doctor.

WHEN TO SEEK MEDICAL ATTENTION

You should contact your healthcare provider if you have any of the following symptoms/situations while on a blood thinner:

- Bleeding that persists after holding pressure for several minutes
- Persistent headaches, weakness, or dizziness
- Dark red or brown urine
- Dark-colored or bloody stools
- Coughing or vomiting blood
- Excessive bruising
- Abnormally heavy menstrual bleeding or bleeding between periods
- A fall
- A head injury
- A car accident or other trauma

Interested in learning more about nuisance bleeding? Check out our June Patient Pulse webinar. Dr. Pynnonen joins us for a more in-depth overview on epistaxis (nosebleeds) and offers step-by-step video instructions on stopping and managing nosebleeds at home.
PH is high blood pressure in the arteries of the lungs. After your blood carries oxygen to the tissues in your body, it returns to the right side of the heart. The right heart then pumps blood into your lungs to get oxygenated again. The pressure that the right heart pumps against is called the pulmonary pressure, and PH occurs when this pressure is too high. If PH is left unattended, the right heart has to work much harder to pump blood to the lungs. This increased workload on the heart can cause shortness of breath and make it difficult to walk, climb stairs, do housework, etc.

Importantly, there are several medical conditions that can increase pulmonary pressure, so a person can have PH that’s completely unrelated to a blood clot. However, a blood clot in the lungs—a PE—is always the source of CTEPH. CTEPH can develop when many small clots form over time, so it’s possible for patients to develop the condition without knowing that they’ve had a PE before. In fact, CTEPH registries around the world have shown that 25-30% of patients with known CTEPH don’t have a history of PE documented in their patient chart. CTEPH can also affect individuals at any age.

**HOW COMMON IS CTEPH?**

An estimated 3% of PE patients develop CTEPH, but it’s hard to know exactly how many people are affected because CTEPH is underrecognized and underdiagnosed. “It doesn’t have clear-cut symptoms. The big signal is that shortness of breath when a person tries to do something – but that’s a nonspecific symptom that occurs with many medical issues,” Dr. Auger says. “If you’re having shortness of breath and you and your doctor know that you’ve had a PE, it’s a little easier to connect the dots and get to CTEPH. But if you have trouble breathing on exertion for no obvious reason, your healthcare provider should start thinking about pulmonary vascular disease as a possible cause.”

**DIAGNOSIS**

If CTEPH is suspected, your doctor will likely obtain an echocardiogram (echo) to get a sense of what the heart is doing and a ventilation/perfusion (VQ) scan, which is a nuclear medicine study to measure breathing and circulation in the lungs.

Dr. Auger points out that these tests are not diagnostic for CTEPH on their own, but they’ll bring a clinician down the appropriate path. “If you have an echo and VQ scan that are both abnormal, you’re on the right street for diagnosing CTEPH. You just need additional studies to get to the right house.”

Additional testing typically includes a CT scan to detect blood clots, and a pulmonary angiogram, which is a test that uses injectable dye to highlight blockages in the arteries of the lungs. A procedure called a right heart catheterization is also typically performed to accurately measure the extent of PH and right heart strain. It’s appropriate for your doctor to refer you to an expert PH or CTEPH center to assist with diagnosis and treatment.

**TREATMENT**

Unlike many types of PH, CTEPH is potentially curable. “The key thing I want patients to know is that we can cure CTEPH with surgery, and that’s exciting,” exclaims Dr. Auger. “The procedure is called a pulmonary thromboendarterectomy. When the surgeon gets into the pulmonary artery, they carefully peel off the clot material that’s adherent to the artery wall. Afterwards, patients are able to breathe again. It’s remarkable. Quality of life improves dramatically – but the surgery is only able to cure PH and its symptoms. A person’s diabetes, COPD, etc. won’t go away with this surgery and patients will still have to manage those.”

In addition, some patients aren’t surgical candidates. “Sometimes, a surgeon will say to me, ‘I can’t get that clot out, it’s inoperable,’ and then I know I have to move forward with other options,” Dr. Auger explains. “Whether or not CTEPH is operable is strictly a technical consideration determined by the
surgeon; however, patients may have other medical or logistic issues that prevent them from having surgery, or they may not want surgery. The good news is that there are options we can offer patients now that we didn’t have 10 years ago, including balloon pulmonary angioplasty (BPA) and PH medications.

BPA is a procedure that uses balloons to open narrowed or blocked blood vessels and restore blood flow to the lungs. Although the procedure doesn’t remove clots, it helps relieve PH, reduce shortness of breath, and improve exercise capacity. Typically, patients need more than one BPA procedure, but they often experience a difference in symptoms afterwards. “They aren’t cured, but they feel better. They can walk upstairs again, they can go for walks in their neighborhood, etc. Every patient will be different, and their outcome goals will be different. The results will also depend on their age and comorbidities,” says Auger.

Medication is another treatment option. Riociguat is an FDA-approved oral agent for CTEPH patients who can’t have surgery or who still have symptoms after a procedure. This medication is often prescribed in combination with BPA, but some patients use it as standalone therapy.

All CTEPH patients need to be on lifelong anticoagulation (blood thinners) as well, even if they’ve been cured with surgery. The goal is to prevent new clots from forming. Patients have typically received warfarin, but some centers are beginning to move towards direct oral anticoagulants (DOACs) to maximize patient convenience.

COST/INSURANCE CONSIDERATIONS

Insurance coverage will vary from plan to plan, but many insurers, including Medicare, are familiar with CTEPH and either partially or fully cover CTEPH-related services. CTEPH centers throughout the US have staff in place to help patients navigate insurance-related issues.

KEY TAKEAWAYS

- CTEPH is underrecognized, even though it’s curable in many patients. It’s important to get a diagnosis so you can be treated appropriately.
- Talk to your healthcare provider as soon as possible if you have shortness of breath or fatigue that doesn’t resolve, especially if you have a history of blood clots. Anticoagulation alone will not prevent the progression of CTEPH!
- There are several excellent CTEPH centers throughout the US. Patients should use these centers as a resource. The Pulmonary Hypertension Association has a list of comprehensive PH care centers on their website, www.CTEPH.com is another good patient website.
- CTEPH treatment and management have changed dramatically over the past few years. There are many options now that weren’t available even a decade ago!

Dr. Auger is a pulmonologist in the Pulmonary Hypertension, Right Heart Failure and CTEPH Program at the Temple Heart and Vascular Institute and Professor of Medicine at the Lewis Katz School of Medicine at Temple University. Dr. Auger was most recently Director of the CTEPH Program at UCSD Healthcare in San Diego, the nation’s number one CTEPH/pulmonary thromboendarterectomy (PTE) program by volume. He served as Medical Director of UCSD’s PTE program for nearly 20 years.
NATF Board and Staff

**BOARD MEMBERS**

**Samuel Z. Goldhaber, MD**  
President, Founding Director  
Associate Chief and Clinical Director,  
Division of Cardiovascular Medicine  
Section Head, Vascular Medicine  
Director, Thrombosis Research Group  
Brigham and Women's Hospital  
Professor of Medicine  
Harvard Medical School

**John Fanikos, RPh, MBA**  
Treasurer, Founding Director  
Director of Pharmacy Business and Financial Services  
Brigham and Women's Hospital  
Assistant Professor of Clinical Pharmacy Practice  
Northeastern University,  
Massachusetts College of Pharmacy

**Jawed Fareed, PhD**  
Vice President, Founding Director  
Director, Hemostasis and Thrombosis Research Laboratories  
Loyola University Medical Center  
Professor of Pathology and Pharmacology  
Loyola University Medical Center

**Gregory Piazza, MD, MS**  
Director, Chair of the Education Committee  
Staff Physician, Division of Cardiovascular Medicine  
Brigham and Women's Hospital  
Associate Professor of Medicine  
Harvard Medical School

**Christian Ruff, MD, MPH**  
Director, Chair of the Atrial Fibrillation Action Initiative  
Associate Physician, Cardiovascular Medicine Division  
Brigham and Women's Hospital  
Assistant Professor of Medicine  
Harvard Medical School

**Jeanine Walenga, PhD**  
Co-Director, Hemostasis and Thrombosis Research Laboratories  
Professor, Departments of Thoracic-Cardiovascular Surgery and Pathology, Stritch School of Medicine  
Loyola University Medical Center

**STAFF**

**Kathryn Mikkelsen, MBA**  
Executive Director  
KMikkelsen@natfonline.org

**Courtney Anderson**  
Associate Director  
CJohnson@natfonline.org

**Claire Galvin**  
Associate Director  
CGalvin@natfonline.org

**Aviva Schwartz, MA**  
Director, Content Development  
Managing Editor, The Beat  
ASchwartz@natfonline.org